Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?

Eur Urol. 2017 Nov;72(5):e137-e138. doi: 10.1016/j.eururo.2017.05.025. Epub 2017 Jun 9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Double-Blind Method
  • ErbB Receptors*
  • Humans
  • Lapatinib
  • Molecular Targeted Therapy
  • Quinazolines
  • Receptor, ErbB-2
  • Treatment Outcome
  • Urinary Bladder Neoplasms*

Substances

  • Quinazolines
  • Lapatinib
  • ErbB Receptors
  • Receptor, ErbB-2